roksi Posted September 16, 2015 Posted September 16, 2015 Istina, lichni stavovi MT su jedno a partijska politika koju ce da "gura" je nesto drugo - jery - naravno - mora da klimne glavom u pravcu Nationals (neki lokalni "Pravashi" koji su u gistro koaliciji sa Libs) sto je vec danas uradio da bi overio istu - koaliciju- onako kolateralno - znaci - strana 3 u Daily Telegrafu - Malkom before vs Malkom after... I sve se, naravno, razlikuje... Njega ako iko skenja to ce biti mangupi iz njegovih redova... :) hehe, dadada. krenulo je. nego, mnogo se nesto MT smeska, kao da nije svestan da moze da ga zakaci ista sudbina k'o KR, JG & TA.
iDemo Posted September 17, 2015 Posted September 17, 2015 hehe, dadada. krenulo je. nego, mnogo se nesto MT smeska, kao da nije svestan da moze da ga zakaci ista sudbina k'o KR, JG & TA. To bi mu bilo tek drugi put (ukupno) i prvi put kao PMu... Znaci, zna covek sta ga ceka...
roksi Posted September 17, 2015 Posted September 17, 2015 To bi mu bilo tek drugi put (ukupno) i prvi put kao PMu... Znaci, zna covek sta ga ceka... mislis? slava i moc udari u glavu kao malo sta. a pride sto se malkolm video u ovoj ulozi od ihaha.
iDemo Posted September 17, 2015 Posted September 17, 2015 mislis? slava i moc udari u glavu kao malo sta. a pride sto se malkolm video u ovoj ulozi od ihaha. Ma dobro, ne planiram nesto da se stresiram kako god da on prodje... Ne radim "saveznu" adiminstraciju.
Eraserhead Posted September 19, 2015 Posted September 19, 2015 (edited) Japanci jedva gotive Induse, a Kinezi nikoga. EDIT: A ni Indusi. Edited September 19, 2015 by Eraserhead
Shan Jan Posted September 20, 2015 Posted September 20, 2015 Al zato pakistanci vole Kinu vise nego rodjenu majku, mora da je zbog kulturnih slicnosti :D
akibono Posted September 22, 2015 Posted September 22, 2015 Da se usereš, kakvi 'biznismeni'... a ovaj gmaz još svojim izgledom i ponašanjem dodatno izaziva određene porive Šta je cena ljudskog života, bila je 1000$, ali više nije! http://youtu.be/H0P4r9fcy1o Martin Shkreli on Raising Price of AIDS Drug 5,000 Percent: ‘I Think Profits Are a Great Thing’“Well, we needed to turn a profit on this drug,” Shkreli, a former hedge fund manager, said on Monday to the Bloomberg host who asked why his pharmaceutical start up just raised the price of a drug critical to HIV treatments from $13.50 a tablet to $750 overnight.“But my understanding is that, to actually produce this pill, costs what, only a dollar?” the host asked.“It costs very little money to make Daraprim,” Shkreli replied, before listing other costs, like the cost of distribution and patient relations, that go into a drug like this.Shkreli’s company, Turing Pharmaceuticals, bought the rights to Daraprim and immediately hiked the price more than 5,000 percent, The New York Times reported on Monday. Daraprim is considered part of the standard treatment for a potentially life-threatening parasitic infection called toxoplasmosis. It is also used to treat people with compromised immune systems, like AIDS patients.In his former life as a hedge fund manager, Shkreli was accused of urging the FDA to not approve drugs from companies whose stocks he was shorting. Then he started another company that bought the rights to drugs and then raised their prices. The board of that company is currently suing Shkreli for $65 million, the Times reported.But Shkreli appears undaunted. The morning the Daraprim news broke, Shkreli tweeted the defiant lyrics to an Eminem song: “And it seems like the media immediately points a finger at me/So I point one back at em, but not the index or pinkie.” He’s been fighting with critics on Twitter since last night.On Bloomberg on Monday, Shkreli praised the price hike as, basically, absolutely wonderful.“We’re the first company that really focused on this product. And I think that’s a great thing, because ultimately companies before us were actually just giving it away, almost,” Shkreli continued. “The price that they were pricing it at, $13.50, you only needed less than 100 pills, so at the end of the day the price per course of treatment—to save your life!—was only $1,000.”His argument, in a nutshell, is that by charging so much more for the drug, Turing can put money into developing newer, better drugs for toxoplasmosis. Daraprim has been on the market for a long time, he argued (it was approved by the FDA in 1953, according to the Times) and patients “deserve” a new drug. They also "deserve a drug company that's making a fair profit," he said.But organizations that advocate for patients don’t see it that way. The Infectious Diseases Society of America and the HIV Medicine Association called the price hike “unjustifiable” and an expert in infectious diseases told the Times that the medical community isn’t “clamoring for better therapies” that Shkreli insisted are needed.So what is going on here? It turns out that buying rights to drugs—older, even generic drugs—and raising their price sharply has been something of a business model for American pharmaceutical companies of late. Senator and presidential candidate Bernie Sanders (I-Vt.), along with Rep. Elijah Cummings (D-Md.) have been vocal about the problem, and have sent letters demanding more information from companies that do it. Last week, they sent a letter to a company called Valeant, who allegedly raised the price of a heart drug more than 500 percent the day it bought the rights to it. Last year, the pair went after the company that raised the price of Doxycycline, a common antibiotic, from $20 a bottle in 2013 to $1,849 by 2014.Sanders and Cummings sent a letter to Turing on Monday, requesting more information from the company, calling the move “just the latest in a long list of skyrocketing price increases for certain critical medications.”Presidential candidate Hillary Clinton chimed in too, promising she’d have a “plan to take it on” by the following day.Still, Shkreli insists, his company is different from the others, noting larger companies do this, and worse, all the time. “Turing is a very small company, it’s a new company, and we’re not a profitable company. So for us to try to exist and maintain a profit I think is pretty reasonable,” he told CNBC on Monday. “I think profits are a great thing to stay in your corporate existence.”http://www.newsweek.com/martin-shkreli-daraprim-drug-prices-374922
Eraserhead Posted September 22, 2015 Posted September 22, 2015 Clanak u NYT je malo vise informativan
Dagmar Posted September 22, 2015 Posted September 22, 2015 Ma sad ide frust na njega, posle ce i da ga hapse verovatno, ima neku istoriju koja vuce da moze da ode u tom pravcu, a hiljade koji rade to isto ce ko i do sada da nastave sa tim
hazard Posted September 22, 2015 Posted September 22, 2015 Meni je ovde najveći problem što neko može da kupi prava na lek čija je formula stara 62 godine. Formule izmišljene pre 60 godina ne bi trebalo da budu ničija privatna svojina, već znanje koje je svima dostupno, besplatno. Onaj ko je izumeo i platio razvoj tog leka je imao sasvim dovoljno vremena da na njemu zaradi.
Eraserhead Posted September 22, 2015 Posted September 22, 2015 Meni je ovde najveći problem što neko može da kupi prava na lek čija je formula stara 62 godine. Formule izmišljene pre 60 godina ne bi trebalo da budu ničija privatna svojina, već znanje koje je svima dostupno, besplatno. Onaj ko je izumeo i platio razvoj tog leka je imao sasvim dovoljno vremena da na njemu zaradi. Zapravo koliko sam shvatio on je kupio brend a period ekskluzivnosti je odavno istekao i genericki proizvodjaci mogu da prave taj lek ali je malo teze doci do njeg zbog kanala distribucije (sto mi zvuci neverovatno). Inace ovo sto kaze Dagmar da ce da ga hapse je malo veci SF.
Dagmar Posted September 22, 2015 Posted September 22, 2015 To sam napisala jer sam citala neki drugi clanak za njega danas gde pominju da ima/bila je (nisam bas najbolje propratila) neka istraga vezana za prethodne momente njegove karijere. Svakako ne zbog ovoga, stavio svoju cenu na svoju robu.
Recommended Posts